This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


AbbVie Inc.

Drug Names(s): levothyroxine, T4, Elthyrone

Description: Synthroid is a synthetic molecule that is identical to the T4 (L-thyroxine) thyroid hormone produced by the thyroid gland. The mechanisms by which thyroid hormones exert their physiologic actions are not completely understood, but it is thoughtthat their principal effects are exerted through control of DNA transcription and protein synthesis.

T4 diffuses into the cell nucleus and binds to thyroid receptor proteins attached to DNA. This hormone nuclear receptor complex activates genetranscription and synthesis of messenger RNA and cytoplasmic proteins. Thyroid hormones regulate multiple metabolic processes and play an essential role in normal growth and development, and normal maturation of the central nervous system and bone. The metabolic actions of thyroid hormones include augmentationof cellular respiration and thermogenesis, as well as metabolism of proteins, carbohydrates and lipids.

Deal Structure: Abbott and AbbVie
In October 2011, Abbott announced plans to separate into two publicly traded companies, one in diversified medical products and the other in research-based pharmaceuticals. The diversified medical products company will consist of Abbott's existing diversified medical products portfolio, including its branded generic pharmaceutical, devices, diagnostic and nutritional businesses, and will retain the Abbott name. The research-based pharmaceutical company will include Abbott's current portfolio of proprietary pharmaceuticals and biologics and will be named AbbVie. The transaction is expected to be completed by the end of 2012.

In January 2013, Abbott completed the separation of its research-based pharmaceuticals business, which became AbbVie, a new independent biopharmaceutical company. Abbott and AbbVie will share marketing rights on certain products. For the following proprietary pharmaceuticals, AbbVie will have marketing rights in the United...See full deal structure in Biomedtracker

Partners: Abbott Laboratories

Synthroid News

Pink Sheet Abbott Synthroid

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug